Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial

Authors: Yuzhou Huang, Miao Chen, Chen Yang, Jing Ruan, Shuqing Wang, Bing Han

Published: 2022-03-07

DOI: 10.1038/s41375-022-01532-1

Source: Full article

---

Abstract

No abstract found.